Why the study?
Does clopidogrel improve clinical outcomes more effectively in smokers compared to non-smokers with acute coronary syndrome undergoing PCI?
Does clopidogrel improve clinical outcomes more effectively in smokers compared to non-smokers with acute coronary syndrome undergoing PCI?
The 'smoker's paradox' in ACS patients undergoing PCI is largely explained by the lower baseline risk profile of smokers and an enhanced clinical efficacy of clopidogrel in this population.
No takes yet. Share an insight, caveat, or question.
Lower-risk profiles largely explain smoker's paradox; extends observations of differential clopidogrel efficacy by smoking status in ACS.
Kodaira et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: